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OBJECTIVE: To compare health-related quality of life
(HRQoL) among relapsing-remitting multiple sclerosis (RRMS)
patients receiving long-term glatiramer acetate (GA) treatment
with those having similar disease duration but remaining
untreated or treated short-term with GA or beta-interferons.
METHODS: Patients followed in year nine of the prospective,
open-label continuation of the US pivotal study of GA were
consented for this cross-sectional survey [GA Group] at ofﬁce
visits. MS Surveys were presented for home completion and
mail-back. Concurrent RRMS comparators from the North
American Research Committee on MS registry were selected by
matching 4:1 (untreated) and 1:1 (per treatment) on gender,
education level, present age +2 years, and duration of MS
(years). Returned postcards afﬁrming participation prompted
mailed MS Surveys. Each survey included the validated MS
Quality of Life Inventory (MSQLI), and Goodin’s MS Ques-
tionnaire (disability), satisfaction with life, health, therapy, and
sociodemographic characteristics. Matched paired comparisons
used Hotelling multivariate T-square analysis and McNemar’s
test. RESULTS: Response rates were 94.8% for GA Group and
78.4% for comparators. The GA Group reported signiﬁcantly
more life satisfaction (Mean [M]: 2.20 vs. 3.03; 95%CI = 0.03,
1.45) and better health on the Mental Component Summary
score (M: 49.55 vs. 44.59; 95%CI = -10.43, -0.09) of the
SF-36 in the MSQLI than matched untreated comparators.
Relative to matched comparators treated with short-term GA
or beta-interferons, the GA Group had signiﬁcantly lower mean
disability scores and better health on the Physical Component
Summary score of the SF-36 and they reported greater satisfac-
tion with therapy. CONCLUSION: This comparative study of
HRQOL suggests that patients with RRMS who have been
treated with GA long-term have realized more life satisfaction
and better mental health than those with a similar disease dura-
tion who remain untreated, and their physical function may be
better than those who have been treated short-term with GA or
beta-interferons.
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OBJECTIVE: To assess the relationship between changes in
patient-reported QoL, disease level and functional status after
three months on natalizumab (TYSABRI). METHODS: MS
patients who received their 3rd natalizumab infusion and were
enrolled in the manufacturer’s restricted distribution program
(TOUCH), participated in a 20-minute cross-sectional internet or
telephone survey. Outcome measures included overall quality of
life (QoL) change since initiating natalizumab using a 3-point
scale (1—worse, 2—no change, 3—better), and pre/post disease
level and functional status change. Disease level was measured on
a 7 point scale: 0—“normal with no limitations on activity”
through 6—“wheelchair bound” whereas functional status was
measured on a 5 point scale: 1—“able to carry out usual daily
activities” through 5—“required assistance”. Paired and inde-
pendent sample t-tests were used based on the outcome metric.
RESULTS: Results from 319 patients in this ongoing survey
(expected n  400) indicated that 75% were female. Overall
QoL improved among 47% of patients, even in the short time on
natalizumab. Only 3% of patients reported a worsening in QoL.
On average, these patients were diagnosed with MS 15 years ago
compared with the sample mean of 11 years. Increases in mean
disease level change scores (0.30  1.13, p < 0.001) and func-
tional status change scores (0.36  0.80, p < 0.001) were
reported, indicating signiﬁcant improvements. Compared to
patients reporting no change or worsening QoL, patients report-
ing improved QoL had signiﬁcantly higher mean disease change
scores (0.56  1.28 vs. 0.08  0.92, p < 0.001) and functional
status change scores (0.71  0.82 vs. 0.04  0.63, p < 0.001).
CONCLUSION: After three months on natalizumab, patients
reported improvements in overall QoL, disease level and func-
tional status. These outcomes were positively and signiﬁcantly
associated with one another suggesting that, in a real world
setting, patients may begin experiencing improvements in disease
progression and QoL as early as three months after natalizumab
initiation.
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OBJECTIVE: To assess multiple sclerosis (MS) patient-reported
experiences with natalizumab (TYSABRI) in a real-world setting.
METHODS: MS patients who received their 3rd natalizumab
infusion and were enrolled in the manufacturer’s restricted dis-
tribution program (TOUCH), participated in a 20-minute cross-
sectional internet or telephone survey. Patient-reported measures
included an adapted version of the Multiple Sclerosis Impact
Scale-29 (MSIS-29), pre/post disease level and functional status
scores and prior MS drug use. MSIS-29 responses were modiﬁed
to measure patient-perceived change since initiating natalizumab.
Paired t-tests assessed pre/post changes in disease level and func-
tional status, where positive change indicated improvement.
RESULTS: Results from 319 patients in this ongoing survey
(expected n  400) indicated that 75% were female and, on
average, were diagnosed with MS over 11 years ago. Almost all
(97%) patients used 1 MS drug before natalizumab. The most
frequently used drugs were: interferon beta-1a (Avonex) (67%),
glatiramer acetate (Copaxone) (49%), interferon beta-1b (Beta-
seron) (36%) and interferon beta-1a (Rebif) (35%). Despite the
short treatment duration, there were signiﬁcant improvements in
disease level (0.30  1.13; t = 4.78; p < 0.001) and functional
status (0.36  0.80; t = 7.96; p < 0.001). MSIS-29 items with
greatest reported improvement since initiating natalizumab were:
“worries related to MS” (66%), “feeling unwell” (64%), ability
to do “physically demanding tasks” (63%), “problems with
balance” (61%), “feeling mentally fatigued” (61%) and “difﬁ-
culties moving about indoors” (60%). Items with least reported
improvement were: “tremors of your arms or legs” (49%),
“being stuck at home” (49%), “problems sleeping” (49%) and
“problems using transport” (42%). On average, patients
reported improvement on 13 of 29 (45%) MSIS-29 items. CON-
CLUSION: After only 3 months on natalizumab, patients
reported improvements on MSIS-29 items, disease level and func-
tional status. While preliminary, these early results are suggestive
of natalizumab’s beneﬁcial effect on patients and warrant further
long term investigation of its impact on patient outcomes in a
real-world setting.
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